Core Insights - Kexing Biopharmaceutical Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, with CITIC Jinshi International as the sole sponsor [1] - The company is an innovative and internationally developed biopharmaceutical firm, focusing on the research, production, and commercialization of recombinant proteins, antibodies, and targeted delivery therapies [1] - Kexing is one of the earliest established biopharmaceutical companies in China and is a key industrialization base for the national "863" program [1] Revenue Sources - The main revenue sources during the reporting period include four self-commercialized products and two introduced products: - SINOGEN (Interferon α1b injection) - EPOSINO (Erythropoietin injection) - WHITE-C (Granulocyte colony-stimulating factor injection) - CLOBICO (Clostridium butyricum live bacteria powder/capsule) - Apexelsin (Paclitaxel injection) - Reminton (Infliximab injection) [1]

Core Viewpoint - Sinovac Biotech Ltd. has submitted its listing application to the Hong Kong Stock Exchange, with CITIC Securities International as the sole sponsor, highlighting its focus on innovative biopharmaceuticals and international development [1]. Group 1: Company Overview - Sinovac Biotech is an innovative and internationally developed biopharmaceutical company, specializing in the research, production, and commercialization of recombinant proteins, antibodies, and targeted delivery therapies [1]. - The company is one of the earliest established biopharmaceutical enterprises in China and is recognized as one of the first industrialization bases under the national "863" program [1]. Group 2: Revenue Sources - During the historical performance period, Sinovac Biotech's primary revenue sources include four self-commercialized products and two introduced products, which are: - SINOGEN (Interferon α1b injection) - EPOSINO (Erythropoietin injection) - WHITE-C (Granulocyte colony-stimulating factor injection) - CLOBICO (Clostridium butyricum live bacteria powder/capsule) - Apexelsin (Paclitaxel injection) - Reminton (Infliximab injection) [1].